Value Rich CoverageCleveland BioLabs is featured on Value Rich (iValueRich.com) and the Spring 2007 Issue of Value Rich Magazine
The article notes, “ Cleveland BioLabs is generating excitement with a potential Department of Defense Contract for its lead radiation compound, an ongoing Phase II clinical trial for its oral anti-cancer compound; and animal data on its stem cell application.”
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute.